Arena Pharmaceuticals Current Ratio 2006-2021 | ARNA

Arena Pharmaceuticals current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Arena Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.99B $0.07B 15.28
2021-03-31 $1.12B $0.05B 23.61
2020-12-31 $1.14B $0.06B 19.62
2020-09-30 $1.20B $0.05B 23.17
2020-06-30 $1.20B $0.04B 28.75
2020-03-31 $0.83B $0.04B 18.68
2019-12-31 $0.76B $0.05B 16.90
2019-09-30 $0.81B $0.04B 21.90
2019-06-30 $1.03B $0.03B 36.51
2019-03-31 $1.13B $0.03B 35.51
2018-12-31 $0.46B $0.03B 15.40
2018-09-30 $0.57B $0.02B 26.08
2018-06-30 $0.60B $0.02B 28.75
2018-03-31 $0.65B $0.04B 15.28
2017-12-31 $0.28B $0.07B 3.89
2017-09-30 $0.30B $0.07B 4.42
2017-06-30 $0.14B $0.05B 3.21
2017-03-31 $0.09B $0.05B 1.85
2016-12-31 $0.12B $0.06B 1.88
2016-09-30 $0.14B $0.06B 2.23
2016-06-30 $0.14B $0.06B 2.56
2016-03-31 $0.16B $0.05B 3.17
2015-12-31 $0.18B $0.05B 3.50
2015-09-30 $0.20B $0.05B 4.21
2015-06-30 $0.24B $0.06B 3.81
2015-03-31 $0.27B $0.07B 3.61
2014-12-31 $0.18B $0.07B 2.70
2014-09-30 $0.21B $0.06B 3.73
2014-06-30 $0.24B $0.06B 3.98
2014-03-31 $0.28B $0.07B 4.13
2013-12-31 $0.25B $0.07B 3.52
2013-09-30 $0.21B $0.06B 3.45
2013-06-30 $0.19B $0.03B 7.16
2013-03-31 $0.15B $0.03B 5.46
2012-12-31 $0.17B $0.03B 5.72
2012-09-30 $0.17B $0.02B 9.34
2012-06-30 $0.17B $0.02B 8.92
2012-03-31 $0.09B $0.01B 7.55
2011-12-31 $0.06B $0.01B 4.20
2011-09-30 $0.08B $0.02B 4.48
2011-06-30 $0.10B $0.02B 5.57
2011-03-31 $0.13B $0.02B 5.63
2010-12-31 $0.16B $0.04B 4.25
2010-09-30 $0.18B $0.04B 4.76
2010-06-30 $0.13B $0.02B 5.78
2010-03-31 $0.11B $0.02B 6.14
2009-12-31 $0.12B $0.02B 5.86
2009-09-30 $0.15B $0.02B 6.91
2009-06-30 $0.05B $0.03B 1.68
2009-03-31 $0.08B $0.04B 1.91
2008-12-31 $0.12B $0.05B 2.48
2008-09-30 $0.22B $0.03B 6.79
2008-06-30 $0.28B $0.05B 6.36
2008-03-31 $0.35B $0.04B 8.94
2007-12-31 $0.41B $0.03B 13.51
2007-09-30 $0.35B $0.04B 9.43
2007-06-30 $0.38B $0.04B 10.75
2007-03-31 $0.37B $0.03B 11.16
2006-12-31 $0.40B $0.04B 11.10
2006-09-30 $0.26B $0.03B 9.25
2006-06-30 $0.28B $0.02B 11.63
2006-03-31 $0.30B $0.03B 11.03
2005-12-31 $0.14B $0.03B 5.29
2005-09-30 $0.15B $0.06B 2.46
2005-06-30 $0.17B $0.06B 2.98
2005-03-31 $0.17B $0.05B 3.17
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.705B $0.000B
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their first and only drug approved by any regulatory agency for marketing. BELVIQ was approved by the US Food and Drug Administration, or FDA, for marketing in the United States, and was made available by prescription in June 2013 to adults who are overweight with a comorbidity or obese. They are exploring BELVIQ for possible new indications, using different formulations, and in combination with other drugs.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71